A health care technology executive, Kevin Lilly provided biotechnology, medical device, and software solutions as senior vice president of sales at MiMedx Group, Inc. In this position, Kevin Lilly assisted MiMedx in expanding operations in US and global human cells, tissues, and cellular or tissue-based products markets.
A leading company in the placental biologics sector, MiMedx creates regenerative medicine using birth tissue as a platform. In March 2021, the company was awarded a Group Purchasing Agreement for the Synergizing for Unparalleled Results in Procurement and Strategic Sourcing (SURPASS) purchasing program by Premier, Inc. The Regenerative Skin Grafting Products agreement stipulates SURPASS members can choose to receive special terms and pricing for MiMedx's advanced wound care product utilizing placental-based tissue.
The agreement aids MiMedx in furnishing health care solutions at a reduced cost and enhances its place in the advanced wound care market. A health care improvement company, Premier works with more than 200,000 providers and 4,100 US hospitals.
